Cardio Hikes On Results Reveal
Date
4/29/2024 10:12:51 AM
(MENAFN- Baystreet) Collective Audience Takes off on Insticator LINK
Intel Floundered Amid Foundry Hopes: What Happened?
These
Pharmaceutical Firms are on Sale: AbbVie, Pfizer, and Gilead
Paramount Global Stronger on Hints of Sacking CEO
Domino's Pizza Beats Earnings Forecasts As Sales Accelerate Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Monday, April 29, 2024
Cardio Hikes on Results Reveal
Shares in Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) were higher Monday. The company, a leader in the next generation of precision cardiovascular medicine technologies that combine proprietary AI algorithms with epigenetic and genetic biomarkers, today announced the publication of results from a budget impact modeling study for PrecisionCHDTM, the Company's AI-powered multiomic coronary heart disease detection test.
The peer-reviewed study“The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs” published in Advances in Therapy, reported that the use of PrecisionCHD can significantly reduce the cost of secondary prevention for stable coronary heart disease (CHD) by up to $113.6 million per year for a typical health insurance plan with one million members.
PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD. This blood-based test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics being recently published in the Journal of American Heart Association.
CDIO shares climbed three cents, or 4.3%, to 72 cents.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN29042024000212011056ID1108151772
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.